[1] 夏换兰, 陆标明, 何凤平,等. 佛山市三水区体检人群非酒精性脂肪肝流行病学调查及相关危险因素分析[J]. 解放军预防医学杂志, 2020, 38(1):50-52. [2] 许旌,杨立,师璇,等. 老年非酒精性脂肪性肝病患者100例的认知功能观察和临床特点[J]. 中华消化杂志, 2019,39(1):35-39. [3] 中华医学会肝脏病学分会脂肪肝和酒精性肝病组. 非酒精性脂肪肝诊断标准[J]. 肝脏, 2001, 6(3):1. [4] Govaere O, Cockell S, Tiniakos D, et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis[J]. Sci Transl Med, 2020, 12(572):eaba4448. [5] Khan A, Ding Z, Ishaq M, et al. Understanding the effects of gut microbiota dysbiosis on nonalcoholic fatty liver disease and the possible probiotics role: recent updates[J]. Int J Biol Sci, 2021, 17(3):818-833. [6] Choi Y, Oh JE, Lee J, et al. Relationship between nonalcoholic fatty liver disease and high sensitivity C-reactive protein in healthy adults[J]. J Fam Practice, 2021, 11(1):39-45. [7] Hoffmann P, Jung V, Behnisch R, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: a cross-sectional and longitudinal analysis[J]. World J Gastroenterol, 2020, 26(46):7367-7381. [8] Celebi G, Cicek AF, Gurel H, et al. Microvesicular steatosis: a missed item in the management of nonalcoholic fatty liver disease?[J]. Acta Gastro-Enterologica Belgica, 2020, 83(4):565-570. [9] Michalak A, Cicho-Lach H, Guz M, et al. Towards an evaluation of alcoholic liver cirrhosis and nonalcoholic fatty liver disease patients with hematological scales[J]. World J Gastroenterol, 2020, 26(47):7538-7549. [10] Kogiso T, Tokushige K . The current view of nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Cancers, 2021, 13(3):516. [11] 王彦丽,郝礼森,张铁强,等.非酒精性脂肪性肝病患者外周血T细胞亚群的变化及意义[J].实用预防医学,2018,25(12):1473-1475. [12] 田甜, 胡文炜, 李雪,等. 非肥胖人群非酒精性脂肪性肝病代谢特征及危险因素分析[J]. 临床肝胆病杂志, 2020, 36(6):120-123. [13] 徐静远, 邵勇, 鲁晓岚, 等. 老年居民非酒精性脂肪性肝病的影响因素和死因分析[J]. 中华肝脏病杂志, 2019, 27(3):204-209. [14] 刘丽娟, 汤旭磊, 甄东户,等. 兰州市社区40~75岁人群非酒精性脂肪性肝病发病与消退影响因素研究[J]. 中国预防医学杂志, 2019, 20(4):298-302.
2022, Vol. 29 
